| ABBV Stock | | | USD 177.06 0.11 0.06% |
Director
Mr. Glenn Fletcher Tilton is an Lead Independent Director of the Company. Mr. Tilton was chairman of the Midwest for JPMorgan Chase Co. from 2011 until his retirement in 2014. From October 2010 to December 2012, Mr. Tilton also served as the nonexecutive chairman of the board of United Continental Holdings, Inc. From September 2002 to October 2010, he served as chairman, president and chief executive officer of UAL Corporationrationration, and chairman and chief executive officer of United Air Lines, Inc., its wholly owned subsidiary. Prior to becoming the vice chairman of Chevron Texaco following the merger of Texaco Inc. and Chevron Corporationration, Mr. Tilton enjoyed a 30year multidisciplinary career with Texaco Inc., culminating in his election as chairman and chief executive officer. Mr. Tilton is also a director of Abbott Laboratories and Phillips 66. Mr. Tilton also served on the board of directors of Lincoln National Corporation from 2002 to 2007, of TXU Corporation from 2005 to 2007, of Corning Incorporated from 2010 to 2012, and of United Continental Holdings, Inc. from 2010 to 2012. since 2013.
| Age | 72 |
| Tenure | 11 years |
| Address | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
AbbVie Management Efficiency
The company has return on total asset
(ROA) of
0.0772 % which means that it generated a profit of $0.0772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
0.5641 %, meaning that it created $0.5641 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AbbVie's
Return On Capital Employed is fairly stable compared to the past year.
Return On Equity is likely to climb to 0.65 in 2024, whereas
Return On Tangible Assets are likely to drop 0.1 in 2024. At this time, AbbVie's
Other Assets are fairly stable compared to the past year.
Non Currrent Assets Other is likely to climb to about 8.9
B in 2024, whereas
Non Current Assets Total are likely to drop slightly above 57.7
B in 2024.
AbbVie Inc currently holds 59.38
B in liabilities with Debt to Equity
(D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AbbVie's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | DIRECTOR Age |
| Raquel MS | HCW Biologics | N/A |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 50000 people. AbbVie Inc (ABBV) is traded on New York Stock Exchange in USA. It is located in 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 and employs 50,000 people. AbbVie is listed under Biotechnology category by Fama And French industry classification.
Management Performance
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Azita Gerhardt, Executive Vice President - Operations | |
| Carlos Alban, Vice Chairman, Chief Commercial Officer | |
| Robert Michael, Vice Chairman, Finance and Commercial Operations and Chief Financial Officer | |
| Jeffrey Stewart, Executive Vice President, Chief Commercial Officer | |
| Carrie Strom, Senior Vice President AbbVie and President Global Allergan Aesthetics | |
| Brett Hart, Independent Director | |
| William Chase, Executive Vice President - Finance and Administration | |
| Roxanne Austin, Independent Director | |
| Perry Siatis, General VP | |
| Azita SalekiGerhardt, Executive Vice President - Operations | |
| Scott Reents, Executive CFO | |
| Thomas Freyman, Independent Director | |
| Thomas MD, Senior Research | |
| Edward Rapp, Independent Director | |
| Richard Gonzalez, Chairman, CEO and Chairman of Executive Committee | |
| Tracie Haas, Brand Responsibility | |
| Sanjay Narayan, Chief SVP | |
| Brian Durkin, Vice President Controller | |
| Frederick Waddell, Independent Director | |
| Robert Alpern, Independent Director | |
| Thomas Hudson, Senior Vice President Research & Development and Chief Scientific Officer | |
| Roopal MD, Executive Officer | |
| Glenn Tilton, Lead Independent Director | |
| Assil Omar, VP Officer | |
| Greg Miley, Senior Affairs | |
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | |
| Elizabeth Shea, Senior Relations | |
| Rebecca Roberts, Independent Director | |
| Edward Liddy, Independent Director | |
| William Burnside, Independent Director | |
| Elaine Sorg, Senior Vice President U.S. Commercial Operations | |
| WulffErik Borcke, Senior Oncology | |
| Timothy Richmond, Chief Human Resource Officer, Executive Vice President | |
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | |
| Laura Schumacher, Executive VP of Bus. Devel. and External Affairs, General Counsel and Corporate Secretary | |
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | |
| Melody Meyer, Independent Director | |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to
measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to
predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.